Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin and Pembrolizumab + Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
NCT05922904Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2023
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin, pembrolizumab in classic Hodgkin lymphoma (cHL), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2023; status: active, not recruiting.
02
Drugs
brentuximab vedotinpembrolizumab
03
Conditions
classic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05922904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05922904.